Physician profile
Aravind Herle
NPI 1851327951
$7,575.45
in general payments reported to CMS, 2019-2025
32 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,551 · 2020: $138 · 2021: $932 · 2022: $272 · 2023: $552 · 2024: $204 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450 · Travel and Lodging: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.77 |
| Travel and Lodging | $232.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,901.32 | 2019-2025 | Amplatzer Amulet, Jot Dx |
| Impulse Dynamics (USA) INC. | $756.73 | 2022-2025 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $656.57 | 2019-2025 | |
| Amgen INC. | $337.87 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.51 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $303.86 | 2019 | |
| Boston Scientific Corporation | $291.29 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $249.63 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $234.05 | 2019-2024 | |
| Akcea Therapeutics, INC. | $204.97 | 2019-2020 | |
| Esperion Therapeutics, INC. | $202.04 | 2023-2025 | Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $200.19 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $176.71 | 2019-2021 | |
| Edwards Lifesciences Corporation | $146.51 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $89.10 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $69.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $63.79 | 2021 | |
| Bridgebio Pharma, INC. | $54.65 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $43.52 | 2019 | |
| Biotronik INC. | $42.05 | 2019 | |
| Gilead Sciences, INC. | $30.40 | 2019 | |
| Cardiofocus, INC. | $27.44 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.86 | 2023 | Onpattro |
| Medtronic, INC. | $22.76 | 2025 | Symplicity G3 |
| Kowa Pharmaceuticals America, INC. | $20.30 | 2021 | |
| Astellas Pharma US INC | $19.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.11 | 2019 | |
| Scpharmaceuticals INC. | $16.31 | 2024 | |
| Daiichi Sankyo INC. | $16.02 | 2019 | |
| Philips North America LLC | $14.38 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $14.37 | 2021 | |
| Portola Pharmaceuticals, LLC | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aravind Herle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.